Merck To Pay Up To $425m For Foghorn’s Gene Regulation Therapies
Major Deal For ‘Gene Traffic Control’ Company
US major continues its expansion in oncology with an early stage deal with Flagship Pioneering protegés.
You may also be interested in...
Merck & Co. will pay Seattle Genetics $725m up front in cash under the two deals and make a $1bn equity investment in the company, providing financial flexibility to broadly fund the pipeline.
The pandemic is expected to dominate the industry's second quarter earnings calls, which kick off on 16 July, but here are 10 other topics to listen for.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.